H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) today and set a price ...

Narrow-moat Bausch & Lomb reported solid third-quarter earnings ... We sell different types of products and services to both investment professionals and individual investors.

Bausch & Lomb is one of the largest vision care companies in the US. Bausch spun off from its former parent company, Bausch Health, in 2022 and it now operates in three segments: vision care ...

Amid swirling speculation, Bausch + Lomb ($BLCO), a global leader in the contact lens supply industry, is reportedly ...

Bausch + Lomb scaled up its revenue guidance for the year after swinging to a profit in the latest quarter on the back of sales growth in each of its business segments.

live and print products, Cosmetics Business informs and inspires business leaders and decision-makers around the world. With a digital-first strategy, the Group’s Editors write breaking news, product ...

Monday was an eventful day for Bausch + Lomb (NYSE: BLCO). The eye care specialist's major piece of internal news was that it earned its latest Food and Drug Administration (FDA) approval.